Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population

• Published in: International journal of experimental pathology 2013-12, Vol.94 (6), p.355-361
• Main Authors: Branković, Ana, Brajušković, Goran, Nikolić, Zorana, Vukotić, Vinka, Cerović, Snežana, Savić-Pavićević, Dušanka, Romac, Stanka
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Alleles; Case-Control Studies; Disease Progression; Genetic Predisposition to Disease - genetics; genetic variation; Genotype; Humans; Male; Middle Aged; nitric oxide synthase; Nitric Oxide Synthase Type III - genetics; Original; Polymorphism, Single Nucleotide - genetics; Prognosis; prostate cancer; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - genetics; Risk Factors; Serbia - epidemiology; single nucleotide polymorphism
• ISSN: 0959-9673; 1365-2613
• DOI: 10.1111/iep.12045

Summary Genome‐wide association studies (GWAS) have identified over 46 SNPs associated with human prostate cancer (PCa). Some studies have shown correlation of the nitric oxide synthase (NOS) NOS3 gene polymorphisms with the risk and/or progression of PCa. This study aimed to evaluate the association of NOS3 gene polymorphisms (−786T>C, −764A>G, −714G>T, −690C>T, −649G>A and 894G>T) with PCa risk and progression. 150 patients with PCa, 150 patients with BPH and 100 age‐matched healthy controls were recruited in this study. Genotyping of promoter polymorphisms was performed by bi‐directional DNA sequencing, and for 894G>T by RFLP analysis. There was no significant association between the alleles and genotypes of these genetic variants and PCa risk. For −786T>C polymorphism, we found that C allele is associated with absence of metastases, assuming dominant genetic model (P = 0.049; OR, 0.50; 95% CI, 0.25–1.00). It was found that, compared with NOS3 −690C>T variant CC genotype, CT and TT genotypes confer decreased risk of developing metastases (dominant model, P = 0.015, OR, 0.24; 95% CI, 0.07–0.88) and show association with low clinical tumour stage, compared with stages T3 and T4 (dominant model, P = 0.046, OR, 0.20; 95% CI, 0.04–1.02). Genetic variants −764A>G, −714G>T, −649G>A were not detected in our study group. There is evidence of an inverse correlation of the NOS3 894G>T minor allele with high serum PSA (>20 ng/ml) (dominant model, P = 0.013, OR, 0.37; 95% CI, 0.17–0.82). Our results suggest that NOS3 gene polymorphisms are genetic susceptibility factors for the progression of PCa and patient outcome.